Logo
x

Search

Subscribe Now

All Posts by Date

Insights+: The US FDA New Drug Approvals in March 2022

Insights+: The US FDA New Drug Approvals in March 2022

  • April 21, 2022
Servier Publishes Results of Tibsovo (ivosidenib) in P-III (AGILE) Trial for IDH1-Mutated Acute Myeloid Leukemia in NEJM

Servier Publishes Results of Tibsovo (ivosidenib) in P-III (AGILE) Trial for IDH1-Mutated Acute Myeloid Leukemia in NEJM

  • April 21, 2022
Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in P-II/III (Orbit) Study for the Treatment of Osteogenesis Imperfecta

Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in P-II/III (Orbit) Study for the Treatment of Osteogenesis Impe...

  • April 21, 2022
Otonomy Reports Results of OTO-413 in P-IIa Clinical Trial for the Treatment of Hearing Loss

Otonomy Reports Results of OTO-413 in P-IIa Clinical Trial for the Treatment of Hearing Loss

  • April 21, 2022
AstraZeneca Reports Results of Evusheld in P-III (PROVENT) Trial for the Treatment of Symptomatic COVID-19

AstraZeneca Reports Results of Evusheld in P-III (PROVENT) Trial for the Treatment of Symptomatic COVID-19

  • April 21, 2022
Vertex Receives the Health Canada Marketing Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat Cystic Fibrosis

Vertex Receives the Health Canada Marketing Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat C...

  • April 21, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.